Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
NEW YORK, Sept. 06, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased American Renal Associates Holdings, Inc. (NYSE:ARA) (“ARA” or “the Company”) securities (1) pursuant and/or traceable to the Initial Public Offering on or about April 21, 2016; and/or (2) between April 21, 2016 and August 18, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/american-renal-associates. There is no cost or obligation to you.
According to the complaint, during the Class Period, ARA made false and/or misleading statements and/or failed to disclose that: (1) ARA was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for ARA’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, ARA’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you suffered a loss in ARA you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/american-renal-associates.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
